CIN: L24100MH1988PLC343805

Reg.Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251

REMEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

30th May, 2025

To,
BSE LIMITED
P J Towers
Dalal Street, Fort,
Mumbai 400 001

Scrip Code : 539561

Dear Sir/Madam,

Reference: Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements), Regulation, 2015
Sub.: Outcome of Board meeting held on Friday, 30th May, 2025

We wish to inform you that, the Board of Directors of the Company, at its meeting held today **Friday, 30th May, 2025** has *inter- alia* considered, approved and taken on record:

1. The Audited Financial Results (Standalone and consolidated) of the Company for the last quarter and year ended March 31, 2025 and Audited Annual Accounts of the Company the quarter and year ended 31st March, 2025 are annexed herewith as **Annexure-I.**

   Please find enclosed herewith the Summarized audited Financial Results (Standalone and consolidated) for the last quarter & year ended March 31, 2025 and the Auditors report on the Financial Results for your kind information and records. Extract of Audited financial results (Standalone and consolidated) would also be published in one English and one vernacular newspaper as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. Appointment of Ms. Riddhi Shah, a Peer Reviewed, Practicing Company Secretaries as Secretarial Auditors of the Company for a period of 5 consecutive financial years commencing from FY 2025-26 till FY 2029-2030, subject to approval of shareholders of the Company at the ensuing 36th Annual General Meeting, to conduct the secretarial audit.

   The details as required under Regulation 30 read with Part A of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are annexed herewith as **Annexure-II.**

3. Appointed Mr. Bikram Kumar Mund (DIN: 06919513) as an Additional/Non- Executive/Independent Director of the company for a first term of five years w.e.f. 30th May, 2025 till 29th May, 2030, subject to the approval of the members at the next General meeting or within three months from the date of appointment, whichever is earlier.

Mr. Bikram Kumar Mund (DIN: 06919513) is not related to any Directors of the Company. In terms of directions issued by SEBI dated 14th June, 2018, we hereby affirm that Mr. Bikram Kumar Mund (DIN: 06919513) is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The details as required under Regulation 30 read with Part A of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are annexed herewith as **Annexure-III.**

4. Appointed Mr. Vijay Pal Singh Gulya (DIN: 01433784) as an Additional/Non- Executive/Independent Director of the company for a first term of five years w.e.f. 30th May, 2025 till 29th May, 2030, subject to the approval of the members at the next General meeting or within three months from the date of appointment, whichever is earlier.

   Mr. Vijay Pal Singh Gulya (DIN: 01433784) is not related to any Directors of the Company. In terms of directions issued by SEBI dated 14th June, 2018, we hereby affirm that Mr. Vijay Pal Singh Gulya (DIN: 01433784) is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

   The details as required under Regulation 30 read with Part A of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are annexed herewith as **Annexure-III.**

5. Appointed Mr. Kapil Goplani (Membership No. A51763 of ICSI) as Company Secretary cum compliance officer of the company under the Companies Act, 2013 read with Regulation 6 of the SEBI (LODR) Regulations, 2015 w.e.f. 1st June, 2025. Details required under Regulation 30 of listing regulation read with SEBI circulars are given in the **Annexure IV.**

CIN: L24100MH1988PLC343805
Reg.Office : Office No.9, K Raheja Prime Sagbaug Road, Marol, Andheri (East), Mumbai - 400059
info@remediumlifecare.com
+91 8433895251

6. **Submission of details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings as per SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023:**

(Amount in Lakh)

Sr. No.	Nature of outstanding	As on 01/04/2024	As on 31/03/2025
1	Outstanding Qualified Borrowings	**NIL**	**NIL**
2	Highest credit rating	**NA**	**NA**
3	Incremental borrowing done	**NA**	**NA**
4	Borrowings by way of issuance of debt securities	**NA**	**NA**
5	Networth	**4329.51**	**4295.78**

Declaration with respect to audit report with unmodified opinion:

We hereby declare that the Statutory Auditors of the Company has issued the Auditors Report under the Companies Act, 2013 and Financial Results as prepared under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Financial Year ended on 31st March, 2025 with unmodified opinion.

Declaration of Non applicability of Regulation 32

Declaration of Non applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Statement of Deviation or Variation for Proceeds of Public Issue, Right Issue, Preferential Issue, QIP,) for the quarter ended 31st March, 2025.

The aforesaid Financial Results will be made available on the Company's website at www.remlife.com

Board Meeting commenced at 7:00 p.m. and concluded at 9:30 p.m.

Kindly take the above information on your record and acknowledge.

For **REMEDIUM LIFECARE LIMITED**

REMEDIUM LIFECARE LIMITED MUMBAI

Adarsh Munjal
Whole Time Director
DIN.: 07304004

Encl.: A/a

Annexure – II

Brief Profile of Secretarial Auditor as required under Regulation 30 of listing regulation read with SEBI circular no CIR/CFC/CMD/4/2015 dated September 9, 2015

Sr. No.	Details of events required to be provided	Information of such event(s)
1	~~Reason for change viz, appointment, resignation, removal, death or otherwise~~ Effective date of appointment	Appointment of Riddhi Shah, Peer Reviewed Company Secretaries in Practice (M.No.20168/CP17035) as secretarial Auditor of the Company.
2	Date of Appointment Term of Appointment	Based on the recommendation of the Audit Committee and subject to the approval of shareholders at the ensuing Annual General Meeting, the Board of Directors of the Company have, at their meeting held on May 30, 2025 accorded approval for appointment of Ms. Riddhi Shah, Practicing Company Secretaries, a Peer Reviewed as the Secretarial Auditors for conducting the secretarial audit of the Company for 5 consecutive financial years commencing from FY 2025- 26 till FY 2029-2030.
3.	Brief Profile	Riddhi Shah, Practicing Company Secretaries, a Peer Reviewed, with an aim to be a leading PCS in promoting good Corporate Governance with an objective to provide wide spectrum of quality professional services in the field of Compliance and Secretarial with an aim to facilitate value addition to its clients. She is passionate about her quality of services as she care her Clients profoundly. An associate member of the Institute of Company Secretaries of India (ICSI) having 14 plus years of enriched experience in corporate secretarial filed and specialized in handling the Corporate Law Matters, Conducting Due Diligence. Worked with Reliance, National Stock Exchange, Kalpataru Limited & last with Capri Global Capital Limited.
4.	Disclosure of relationship between the Directors	Not Applicable
5.	Shareholding in the Company	Nil

Annexure – III

a) **Brief Profile of Mr. Bikram Kumar Mund (DIN: 06919513) as required under Regulation 30 of listing regulation read with SEBI circular no CIR/CFC/CMD/4/2015 dated September 9, 2015**

Sr. No.	Details of events required to be provided	Information of such event(s)
1	~~Reason for change viz, appointment, resignation, removal, death or otherwise~~ Effective date of appointment	Appointment of Mr. Bikram Kumar Mund (DIN: 06919513) as an Additional/Non-Executive/Independent/Director of the company for a first term of five years w.e.f. 30th May, 2025 till 29th May, 2030
2	Date of Appointment Term of Appointment	Based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of shareholders at the ensuing General Meeting, the Board of Directors of the Company have, at their meeting held on May 30, 2025 accorded approval for appointment of Mr. Bikram Kumar Mund (DIN: 06919513), an Additional/Non-Executive/Independent Director of the company for a first term of five years w.e.f. 30th May, 2025 till 29th May, 2030.
3.	Brief Profile	B.SC, LL.B., FCS, having 21 years of experience as practicing company secretary, worked as RFO manager for Ministry of Corporate Affairs at Raipur and Jaipur. He has experience in incorporation of company and all sort of filling and consultancy relating to company act.
4.	Disclosure of relationship between the Directors	Not Applicable
5.	Shareholding in the Company	Nil

Annexure – III

b) Brief Profile of Mr. Vijay Pal Singh Gulya (DIN: 01433784) as required under Regulation 30 of listing regulation read with SEBI circular no CIR/CFC/CMD/4/2015 dated September 9, 2015

Sr. No.	Details of events required to be provided	Information of such event(s)
1	~~Reason for change viz, appointment, resignation, removal, death or otherwise~~ Effective date of appointment	Appointment of Mr. Vijay Pal Singh Gulya (DIN: 01433784) as an Additional/Non-Executive/Independent/ Director of the company for a first term of five years w.e.f. 30th May, 2025 till 29th May, 2030
2	Date of Appointment Term of Appointment	Based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of shareholders at the ensuing General Meeting, the Board of Directors of the Company have, at their meeting held on May 30, 2025 accorded approval for appointment of Mr. Vijay Pal Singh Gulya (DIN: 01433784) an Additional/Non-Executive/Independent Director of the company for a first term of five years w.e.f. 30th May, 2025 till 29th May, 2030.
3.	Brief Profile	He is Chartered Accountant with 20 years of experience in Tax and audit.
4.	Disclosure of relationship between the Directors	Not Applicable
5.	Shareholding in the Company	Nil

CIN: L24100MH1988PLC343805

Reg.Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251

REMEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

Annexure – IV

Brief Profile of Mr. Kapil Goplani as required under Regulation 30 of listing regulation read with SEBI circular no CIR/CFC/CMD/4/2015 dated September 9, 2015

Sr. No.	Details of events required to be provided	Information of such event(s)
1	~~**Reason for change viz, appointment, resignation, removal, death or otherwise**~~ **Effective date of appointment**	Appointment of Mr. Kapil Goplani (Membership No. A51763 of ICSI) as Company Secretary cum compliance officer of the company under the Companies Act, 2013 read with Regulation 6 of the SEBI (LODR) Regulations, 2015 w.e.f. 1st June, 2025.
2	**Date of Appointment** **Term of Appointment**	Appointed w.e.f from 1st June, 2025. Not applicable
3.	**Brief Profile**	Qualified as a Company Secretary ACS from the Institute of Company Secretaries of India (ICSI), he has a strong foundation in legal compliance, corporate structuring, and stakeholder communication. As a seasoned Compliance Officer, he has successfully led organizations through complex regulatory landscapes, including SEBI, Companies Act, Listing Obligations, and other statutory requirements with 6 years of experience in Secretarial & Audit Department.
4.	**Disclosure of relationship between the Directors**	Not related
5.	**Shareholding in the Company**	Nil

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar,M.G. Road No.6, Goregaon West. Mumbai- 400 104.Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office:"Deepa - Lakshmi" 106, Kherapati Colony, Gwalior – 474002 (M.P.)

INDEPENDENT AUDITOR'S REPORT ON AUDITED CONSOLIDATED FINANCIAL RESULTS OF REMEDIUM LIFECARE LIMITED ("the Parent") PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To,
The Board of Directors
Remedium Lifecare Limited
(formerly known as Roxy Exports Limited)

Report on the Audit of Consolidated Financial Results

We have audited the accompanying consolidated financial results of Remedium Lifecare Limited (hereinafter referred as to as "the Holding Company") and its subsidiary (Holding Company and its Subsidiary together referred to as "the Group") for the year ended 31st March,2025 ('the statement") attached herewith , being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, based on the consideration of audit report of other auditor on separate unaudited financial result/financial information/financial statement of the subsidiary, referred to in other matter section below, for year ended 31st March 2025:

(i) Includes the financial results of the following entities:
Remlife Global PTE LTD

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the consolidated net profit/loss and other comprehensive income and other financial information of the Group for the quarter and year-to-date period ended 31st March,2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

SANDEEP & ASSOCIATES TAORI FIRM REG No. 007414C CHARTERED ACCOUNTANTS

We believe that the audit evidence by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Director's Responsibilities for the Consolidated Financial Results

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended, issued thereunder, the RBI Guidelines and other accounting principles generally accepted in India and is in compliance with the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors and Management of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors and Management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditors' Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

TAORI SANDEEP & ASSOCIATES FIRM REG No. 007414C CHARTERED ACCOUNTANTS

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information/financial statement of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been unaudited by other auditor, such other auditor remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

TAORI SANDEEP & ASSOCIATES
FIRM REG No. 007414C
CHARTERED ACCOUNTANTS

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar,M.G. Road No.6, Goregaon West. Mumbai- 400 104.Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office:"Deepa - Lakshmi" 106, Kherapati Colony, Gwalior – 474002 (M.P.)

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters

1. The Statement includes the unaudited financial results of one subsidiaries, whose Financial Results reflect Group's share of total assets of Rs. 18076.55 Lakhs (before consolidation adjustments) as at March 31, 2025, Group's share of total revenue of Rs. 18275.35 Lakhs (before consolidation adjustments), Group's share of total net profit after tax of Rs. 59.74 Lakhs (before consolidation adjustments), and Group's share of total comprehensive income of Rs. 59.74 Lakhs (before consolidation adjustments) for the period from April 01, 2024 to March 31, 2025 and Group's net cash inflow of Rs. 6.36 Lakhs (before consolidation adjustments) for the year ended as on date respectively, as considered in the Statement, which have been audited by other auditors whose reports on financial results of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.
2. The Subsidiary was incorporated on 24th September 2024 but business operations of the company started from quarter ended 31st March 2025. The subsidiary is based in Singapore which follows calendar year of accounting, therefore current quarter's financial result/financial information/financial statement is prepared on unaudited basis.

Our opinion is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditor

TAORI SANDEEP & ASSOCIATES FIRM REG No. 007414C CHARTERED ACCOUNTANTS

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar,M.G. Road No.6, Goregaon West. Mumbai- 400 104.Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office:"Deepa - Lakshmi" 106, Kherapati Colony, Gwalior – 474002 (M.P.)

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the LODR Regulations. Our opinion on the Audit of the Consolidated Financial Results for the year ended 31st March, 2025 is not modified in respect of the above matters.

For TAORI SANDEEP & ASSOCIATES
Chartered Accountants
Firm Registration No. : 007414C

Place: Mumbai
Date: 30th May,2025
UDIN: 25048920BMNQNM3066

TAORI SANDEEP & ASSOCIATES FIRM REG. No. 007414C CHARTERED ACCOUNTANTS

Atul

CA Atul Jain
(Partner)
M. No. : 048920

REMEDIUM LIFECARE LIMITED
REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Statement of Audited Consolidated Financial Results for the Quarter and Year ended March 31, 2025

(₹ in Lakh - Except per Share Data)

Particulars	Quarter Ended			Year Ended	
	31st March, 2025	31st Dec, 2024	31st March, 2024	31st March, 2025	31st March, 2024
I. Revenue from Operations	26432.27	0.00	0.00	40525.11	0.00
II. Other Income	65.93	0.00	0.00	1080.26	0.00
III. Total Income (I +II)	26498.20	0.00	0.00	41605.37	0.00
IV. Expenses					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	19100.86	0.00	0.00	53428.22	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	7166.03	0.00	0.00	-13614.71	0.00
Employee Benefits Expenses	9.27	0.00	0.00	75.60	0.00
Finance Costs	159.33	0.00	0.00	528.86	0.00
Depreciation and amortisation expenses	0.97	0.00	0.00	3.87	0.00
Other Expenses	201.78	0.00	0.00	745.09	0.00
Total Expenses (IV)	26638.23	0.00	0.00	41166.93	0.00
V. Profit/(Loss) before exceptional items and tax (III- IV)	-140.03	0.00	0.00	438.44	0.00
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-140.03	0.00	0.00	438.44	0.00
VIII. Tax Expense					
(1) Current tax	65.47	-	0.00	226.40	0.00
(2) Deferred tax	-0.91	0.00	0.00	-0.91	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
Total Tax	64.56	0.00	0.00	225.50	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-204.60	-	0.00	212.94	0.00
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-204.60	0.00	0.00	212.94	0.00
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	-204.60	0.00	0.00	212.94	0.00
XVI. Earnings per equity share (for continuing operation):					
(1) Basic	-0.05	0.00	0.00	0.05	0.00
(2) Diluted	-0.05	0.00	0.00	0.05	0.00
XVII. Earnings per equity share (for discontinued operation):					
(1) Basic	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00
XVIII. Earnings per equity share (for discontinued & continuing operations)					
(1) Basic	-0.05	0.00	0.00	0.05	0.00
(2) Diluted	-0.05	0.00	0.00	0.05	0.00

Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on May 30, 2025. The Statutory Auditors have carried out their audit for the above results.

(2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

(3) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.

(4) Income tax in Quarter 4 represent income tax provision for full year.

(5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.

(6) Figures of the quarter ended 31st March, 2025 and 31st March, 2024 are balancing figures between audited figures in respect of full financial year and the year to date figures upto third quarter of the relevant financial year which were subject to limited review by the auditors.

For Remedium Lifecare Limited

REMEDIUM LIFECARE LIMITED MUMBAI

ADARSH MUNJAL
(Whole Time Director)
DIN : 07304004

Date: 30.05.2025
Place : Mumbai

REMEDIUM LIFECARE LIMITED
REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Statement of Audited Consolidated Balance Sheet as at

(₹ in Lakhs)

Particulars	**31st March, 2025**	**31st March, 2024**
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	0.83	-
(b) Capital Work in Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible Assets	-	-
(f) Intengible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financials Assets-		
(i) Investments (in Wholly own Subsidiary)	-	-
(ii) Trade Receivables	-	-
(iii) Loans	-	-
(iv) Other(to be specified)	-	-
(i) Deferred tax assets (net)	3.58	-
(j) Other non-current assets	-	-
Sub-total Non Current Assets	**4.41**	**-**
Current Assets		
(a) Inventories	26,937.77	-
(b) Financials Assets		-
(i) Investments	-	-
(ii) Trade receivables	77,161.98	-
(iii) Cash and cash equivalents	28.15	-
(iv) Bank Balance other than (iii) above	114.57	-
(v) Loans/Advances	67,537.73	-
(vi) Others (to be specified)	-	-
(c) Current tax Assets	-	-
(d) Other current Assets	250.30	-
Sub-total - Current Assets	**1,72,030.49**	**-**
TOTAL ASSETS	**1,72,034.90**	**-**

EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	4,032.00	-
(b) Other Equity	357.11	-
Sub Total Equity	**4,389.11**	-
Liabliaties		
Non -Current liabilites		
(a) Financials Liablities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(iii) Other Financial liablities (other than specified in item (b) to be specified	-	-
(b) Provisions	-	-
(c) Deffered Tax Liabilites (net)	-	-
(d) Other Non-Current Liablities	-	-
Sub Total Non Current Liabilities	-	-
Current Liablities	-	-
(a) Financials Liablities		
(i) Borrowings	1,14,139.31	-
(ii) Trade Payables	50,096.26	-
(iii) Other Financial liablities (other than specified in item (c) tobe specified	-	-
(b) Other current liabilities	3,171.79	-
(c) provisions	238.44	-
(d) Current Tax Liablitries	-	-
Sub Total Non Current Liabilities	**1,67,645.80**	-
TOTAL EQUITY AND LIABILITES	**1,72,034.90**	-

For REMEDIUM LIFECARE LIMITED

REMEDIUM LIFECARE LIMITED MUMBAI

ADARSH MUNJAL
(WHOLE TIME DIRECTOR)
DIN : 07304004
Date: 30.05.2025
Place : Mumbai

REMEDIUM LIFECARE LIMITED
REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Audited Consolidated Cashflow Statement for the Year ended on 31st March,2025

(₹ in Lakhs)

Particulars	***LF***	***As at 31.03.2025***		***As at 31.03.2024***	
A. Cashflow from operating activity					
Net Profit / (Loss) before extraordinary items and tax		438.44		-	
Adjustments for:					
Depreciation and amortisation		3.87		-	
Profit on sale of FA		-		-	
Finance Cost		528.86		-	
Interest Income		-12.89		-	
Operating profit / (loss) before working capital changes			**958.28**		-
Changes in working capital:					
Adjustments for (increase) / decrease in operating assets:					
Inventories		-26,937.77		-	
Trade receivables		-77,161.98		-	
Other Current assets		-250.30		-	
Current Loans and Advances		-63,595.33		-	
Non Current Loans					
Adjustments for increase / (decrease) in operating liabilities:					
Trade payables		50,096.26		-	
Other current liabilities		3,171.79		-	
Current provisions		238.44		-	
Current Tax liabilities					
Cashflow from extraordinary activity					
Cash Generated from operation			**-1,14,438.89**		-
Net Income tax paid			-		-
					-
Net cash flow from / (used in) operating activities(A)			**-1,14,438.89**		-
					-
B. Cash flow from investing activities					
Capital expenditure on fixed assets, including capital advances					
Investment in Subsidiary		-			
Proceeds from sale of fixed assets					
Receipt of Loans & Advances					
Interest received		12.89		-	
-- Others					
Cash flow from extraordinary items			12.89		
Net cash flow from / (used in) investing activities (B)					
C. Cash flow from financing activities					
Proceeds from issue of equity shares		-		-	
Proceeds from Short-term borrowings		1,14,139.31		-	
Finance cost		-528.86		-	
Loan From Director		-		-	

Dividends paid		-		-	
Tax on dividend		-		-	
Net cash flow from / (used in) financing activities (C)			**1,13,610.45**		-
Net Cash flow during the period			142.72		-
Cash and cash equivalents at the beginning of the year			-		-
Cash and cash equivalents at the end of the year			142.72		-
Reconciliation of Cash and cash equivalents with the Balance Sheet:					
Cash and cash equivalents as per Balance Sheet			142.72		-
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 7 "Statements of Cash Flow"					
Net Cash and cash equivalents as defined in AS 7 ("Statement of Cash Flows")			142.72		-
Add: Current investments considered as part of Cash and cash equivalents (as defined in Ind AS 7 ("Statement of Cash Flows")) (Refer Note (ii) to Note 16 Current investments)					
Cash and cash equivalents at the end of the year *			142.72		-
* Comprises					
(a) Cash on hand			28.15		-
(b) Cheques, drafts on hand					
(c) Balances with banks					
(i) In current accounts			114.57		-
(ii) In EEFC accounts			-		-
(iii) In deposit accounts with original maturity of			-		-
less than 3 months			-		-
(iv) In earmarked accounts (give details) (Refer			-		-
Note (ii) below)			-		-
(d) Others (specify nature)			-		-
(e) Current investments considered as part of Cash			-		-
and cash equivalents			-		
Total			**142.72**		-

On behalf of the Board
FOR REMEDIUM LIFECARE LIMITED

ADARSH MUNJAL
WHOLE TIME DIRECTOR
DIN : 07304004

Place: Mumbai
Date: 30.05.2025

INDEPENDENT AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To,
The Board of Directors
Remedium Lifecare Limited
(formerly known as Roxy Exports Limited)

Opinion

We have audited the accompanying annual financial results of **Remedium Lifecare Limited (formerly known as Roxy Exports Limited)** (hereinafter referred to as the "Company") for the year ended 31st March, 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31st March, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in

TAORI SANDEEP & ASSOCIATES FIRM REG No. 007414C

India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company' s financial reporting process

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.

TAORI SANDEEP & ASSOCIATES FIRM REG No. 007414C CHARTERED ACCOUNTANTS

- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters
The standalone annual financial results include the results for the quarter ended 31st March, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For TAORI SANDEEP & ASSOCIATES
Chartered Accountants
Firm Registration No. : 007414C

TAORI SANDEEP & ASSOCIATES FIRM REG No. 007414C CHARTERED ACCOUNTANTS

Atul

Place: Mumbai
Date: 30th May,2025
UDIN: 25048920BMNQNK3598

CA Atul Jain
(Partner)
M. No. : 048920

REMEDIUM LIFECARE LIMITED
REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Statement of Audited Standalone Financial Results for the Quarter and Year ended March 31, 2025

(₹ in Lakh - Except per Share Data)

Particulars	Quarter Ended			Year Ended	
	31st March, 2025	31st Dec, 2024	31st March, 2024	31st March, 2025	31st March, 2024
I. Revenue from Operations	8156.92	3815.08	140849.37	22249.76	404170.67
II. Other Income	65.93	743.07	289.27	1080.26	2108.11
III. Total Income (I+II)	**8222.85**	**4558.14**	**141138.64**	**23330.02**	**406278.78**
IV. Expenses					
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	898.32	7770.12	142230.54	35225.68	412728.50
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	7166.03	-3726.74	1931.29	-13614.71	-12590.97
Employee Benefits Expenses	9.27	20.29	18.31	75.60	84.27
Finance Costs	159.33	88.36	384.72	528.86	387.30
Depreciation and amortisation expenses	0.97	0.97	1.41	3.87	5.67
Other Expenses	200.95	299.24	172.01	744.26	618.59
Total Expenses (IV)	**8434.86**	**4452.23**	**144738.27**	**22963.56**	**401233.35**
V. Profit/(Loss) before exceptional items and tax (III- IV)	**-212.01**	**105.91**	**-3599.64**	**366.46**	**5045.42**
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	**-212.01**	**105.91**	**-3599.64**	**366.46**	**5045.42**
VIII. Tax Expense					
(1) Current tax	53.23	29.47	1774.34	214.17	1774.34
(2) Deferred tax	-0.91	0.00	-1.93	-0.91	-1.93
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
Total Tax	52.33	29.47	1772.41	213.26	1772.41
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	**-264.34**	**76.45**	**-5372.04**	**153.20**	**3273.02**
X. Profit/(Loss) from discontinued operations	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	**-264.34**	**76.45**	**-5372.04**	**153.20**	**3273.02**
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	**-264.34**	**76.45**	**-5372.04**	**153.20**	**3273.02**
XVI. Earnings per equity share					
(1) Basic	-0.07	0.02	-149.22	0.04	90.92
(2) Diluted	-0.07	0.02	-149.22	0.04	90.92

Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on May 30, 2025. The Statutory Auditors have carried out their audit for the above results.

(2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

(3) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.

(4) As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.

(5) Figures of the quarter ended 31st March, 2025 and 31st March, 2024 are balancing figures between audited figures in respect of full financial year and the year to date figures upto third quarter of the relevant financial year which were subject to limited review by the auditors.

For Remedium Lifecare Limited

ADARSH MUNJAL
(Whole Time Director)
DIN : 07304004

Date: 30.05.2025
Place : Mumbai

REMEDIUM LIFECARE LIMITED
REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Statement of Audited Standalone Balance Sheet as at

(₹ in Lakhs)

Particulars	**31st March, 2025**	**31st March, 2024**
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	0.83	4.70
(b) Capital Work in Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible Assets	-	-
(f) Intengible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financials Assets-		
(i) Investments (in Wholly own Subsidiary)	6.51	-
(ii) Trade Receivables	-	-
(iii) Loans	-	-
(iv) Other(to be specified)	-	-
(i) Deferred tax assets (net)	3.58	2.67
(j) Other non-current assets	-	-
Sub-total Non Current Assets	**10.92**	**7.37**
Current Assets		
(a) Inventories	26,937.77	13,323.06
(b) Financials Assets		
(i) Investments	-	-
(ii) Trade receivables	59,091.77	92,060.18
(iii) Cash and cash equivalents	28.15	27.07
(iv) Bank Balance other than (iii) above	108.23	125.32
(v) Loans/Advances	67,537.73	89,038.18
(vi) Others (to be specified)	-	211.17
(c) Current tax Assets	-	-
(d) Other current Assets	250.30	-
Sub-total - Current Assets	**1,53,953.94**	**1,94,784.99**
TOTAL ASSETS	**1,53,964.86**	**1,94,792.36**

EQUITY AND LIABILITES		
Equity-		
(a) Equity Share Capital	4,032.00	1,008.00
(b) Other Equity	297.51	3,287.78
Sub Total Equity	**4,329.51**	**4,295.78**
Liabliaties		
Non -Current liabilites		
(a) Financials Liablities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(iii) Other Financial liablities (other than specified in item (b) to be specified	-	-
(b) Provisions	-	-
(c) Deffered Tax Liabilites (net)	-	-
(d) Other Non-Current Liablities	-	-
Sub Total Non Current Liabilities	-	-
Current Liablities	-	-
(a) Financials Liablities		
(i) Borrowings	1,14,139.31	5,770.25
(ii) Trade Payables	32,098.04	71,228.80
(iii) Other Financial liablities (other than specified in item (c) tobe specified	-	-
(b) Other current liabilities	3,171.79	1,11,670.08
(c) provisions	226.20	1,827.45
(d) Current Tax Liablitries	-	-
Sub Total Non Current Liabilities	**1,49,635.34**	**1,90,496.58**
TOTAL EQUITY AND LIABILITES	**1,53,964.86**	**1,94,792.36**

For REMEDIUM LIFECARE LIMITED

REMEDIUM LIFECARE LIMITED MUMBAI

ADARSH MUNJAL
(WHOLE TIME DIRECTOR)
DIN : 07304004
Date: 30.05.2025
Place : Mumbai

REMEDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059

E-mail: info@remediumlifecare.com;

CIN: L24100MH1988PLC343805

Audited Standalone Cashflow Statement for the Year ended on 31st March,2025

(₹ in Lakhs)

Particulars	*LF*	*As at 31.03.2025*		*As at 31.03.2024*	
A. Cashflow from operating activity					
Net Profit / (Loss) before extraordinary items and tax		366.46		5,045.42	
Adjustments for:					
Depreciation and amortisation		3.87		5.67	
Profit on sale of FA		-			
Finance Cost		528.86		387.30	
Interest Income		-12.89		-9.38	
Operating profit / (loss) before working capital changes			**886.30**		**5,429.01**
Changes in working capital:					
Adjustments for (increase) / decrease in operating assets:					
Inventories		-13,614.71		-12,590.97	
Trade receivables		32,968.41		-74,779.07	
Other Current assets		-39.13		-153.27	
Current Loans and Advances		21,215.89		6,219.41	
Non Current Loans					
Adjustments for increase / (decrease) in operating liabilities:					
Trade payables		-39,130.75		62,707.54	
Other current liabilities		-1,08,498.29		5,964.87	
Current provisions		-1,601.25		1,567.56	
Current Tax liabilities					
Cashflow from extraordinary activity					
Cash Generated from operation			**-1,08,699.84**		**-11,063.93**
Net Income tax paid			49.06		1,781.19
Net cash flow from / (used in) operating activities(A)			**-1,08,748.90**		**-12,845.12**
B. Cash flow from investing activities					
Capital expenditure on fixed assets, including capital advances					
Investment in Subsidiary		-6.51			
Proceeds from sale of fixed assets					
Receipt of Loans & Advances					
Interest received		12.89		9.38	
-- Others					
Cash flow from extraordinary items			6.38		
Net cash flow from / (used in) investing activities (B)					
C. Cash flow from financing activities					
Proceeds from issue of equity shares		-		-	
Proceeds from Short-term borrowings		1,08,369.06		5,770.25	
Finance cost		-528.86		-387.30	
Loan From Director		-		-	
Dividends paid		-		-	
Tax on dividend		-		-	

Net cash flow from / (used in) financing activities (C)	**1,07,840.20**	**5,382.94**
Net Cash flow during the period	-16.01	-2,033.17
Cash and cash equivalents at the beginning of the year	152.39	2,185.56
Cash and cash equivalents at the end of the year	136.38	152.39
Reconciliation of Cash and cash equivalents with the Balance Sheet:		
Cash and cash equivalents as per Balance Sheet	136.38	152.39
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 7 "Statements of Cash Flow"		
Net Cash and cash equivalents as defined in AS 7 ("Statement of Cash Flows")	136.38	152.39
Add: Current investments considered as part of Cash and cash equivalents (as defined in Ind AS 7 ("Statement of Cash Flows")) (Refer Note (ii) to Note 16 Current investments)		
Cash and cash equivalents at the end of the year *	136.38	152.39
* Comprises		
(a) Cash on hand	28.15	27.07
(b) Cheques, drafts on hand		
(c) Balances with banks		
(i) In current accounts	108.23	125.32
(ii) In EEFC accounts	-	-
(iii) In deposit accounts with original maturity of less than 3 months	-	-
(iv) In earmarked accounts (give details) (Refer Note (ii) below)	-	-
(d) Others (specify nature)	-	-
(e) Current investments considered as part of Cash and cash equivalents	-	-
Total	**136.38**	**152.39**

On behalf of the Board
FOR REMEDIUM LIFECARE LIMITED

ADARSH MUNJAL
WHOLE TIME DIRECTOR
DIN : 07304004

REMEDIUM LIFECARE LIMITED MUMBAI

Place: Mumbai
Date: 30.05.2025